menu search

RYZB / RayzeBio sets IPO terms, to be valued at up to $1 billion

RayzeBio sets IPO terms, to be valued at up to $1 billion
RayzeBio Inc. RYZB, has set terms for its initial public offering, as the California-based radiopharmaceutical company with a tumor treatment in a Phase 3 trial looks to raise up to about $238.2 million. A total of 14.4 million shares will be offered in the IPO, with the company offering 13.2 million shares and a selling shareholder offering 1.2 million shares. Read More
Posted: Sep 11 2023, 07:03
Author Name: Market Watch
Views: 110729

RYZB News  

RayzeBio: Initiating Coverage With Buy Rating And A Price Target Of $43

By Seeking Alpha
October 10, 2023

RayzeBio: Initiating Coverage With Buy Rating And A Price Target Of $43

Initiating RayzeBio, Inc. coverage with a Buy rating and common stock price target of $43 based on my risk-adjusted NPV discounted cash flow model, re more_horizontal

RayzeBio stock opens with a big gain, to push valuation up to $1.4 billion

By Market Watch
September 15, 2023

RayzeBio stock opens with a big gain, to push valuation up to $1.4 billion

Investors cheered RayBio Inc. as it debuted on Wall Street, as the California-based radiopharmaceutical company's stock RYZB, +39.13% opened 38.9% abo more_horizontal

RayzeBio to go public at $1B market valuation

By Proactive Investors
September 15, 2023

RayzeBio to go public at $1B market valuation

RayzeBio Inc shares are expected to begin trading on the Nasdaq after Friday's open as the radiopharmaceutical company's upsized initial public offeri more_horizontal

RayzeBio valued at nearly $1 billion as upsized IPO prices at top of expected range

By Market Watch
September 15, 2023

RayzeBio valued at nearly $1 billion as upsized IPO prices at top of expected range

RayzeBio Inc. RYZB, has secured a near-$1 billion market valuation, as the California-based radiopharmaceutical company's upsized initial public offer more_horizontal

RayzeBio sets IPO terms, to be valued at up to $1 billion

By Market Watch
September 11, 2023

RayzeBio sets IPO terms, to be valued at up to $1 billion

RayzeBio Inc. RYZB, has set terms for its initial public offering, as the California-based radiopharmaceutical company with a tumor treatment in a Pha more_horizontal


Search within

Pages Search Results: